A detailed history of Octagon Capital Advisors LP transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Octagon Capital Advisors LP holds 176,000 shares of AUTL stock, worth $526,240. This represents 0.15% of its overall portfolio holdings.

Number of Shares
176,000
Previous 176,000 -0.0%
Holding current value
$526,240
Previous $612,000 4.25%
% of portfolio
0.15%
Previous 0.14%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$5.39 - $7.29 $948,640 - $1.28 Million
176,000 New
176,000 $1.12 Million

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $272M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Octagon Capital Advisors LP Portfolio

Follow Octagon Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Octagon Capital Advisors LP with notifications on news.